<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37130476</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J Clin Virol</ISOAbbreviation></Journal><ArticleTitle>Polio type 2 and 3 eradication: Relevance to the immunity status of individuals living in Germany, 2005-2020.</ArticleTitle><Pagination><StartPage>105471</StartPage><MedlinePgn>105471</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2023.105471</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-6532(23)00094-X</ELocationID><Abstract><AbstractText>Since October 2019, poliovirus type 3 (PV3) has been certified as globally eradicated, and further laboratory use of PV3 will be restricted according to the WHO Polio Eradication Initiative and containment measures. To examine a possible gap in PV3 immunity and a lack of immunity against poliovirus type 2 (PV2), which was already declared as eradicated in 2015, neutralising antibodies against polioviruses (PV) of individuals living in Germany (n = 91,530 samples; mainly outpatients (≈90%) who received immune status testing) were investigated from 2005 to 2020 (age distribution: &lt;18 years 15.8%, 18-64 years 71.2% and ≥65 years 9.5% for 2005-2015; &lt;18 years 19.6%, 18-64 years 67% and ≥65 years 11.5% for 2016-2020). The results showed that the proportion of sera exclusively lacking antibodies against PV3 was 10.6% in 2005-2015 and 9.6% in 2016-2020 and against PV2 2.8% in 2005-2015. As there is decreased protection against PV3 and to detect potential antigenically (immune escape) variant PVs not covered by used vaccines, we recommend continued testing of PV1 and PV3.</AbstractText><CopyrightInformation>Copyright © 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohmer</LastName><ForeName>Niko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany. Electronic address: Niko.kohmer@kgu.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabenau</LastName><ForeName>Holger F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rilling</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciesek</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, 60596, Frankfurt, Germany; German Centre for Infection Research, External Partner Site, 60323, Frankfurt, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), 60596, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enders</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggers</LastName><ForeName>Maren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory Prof. Gisela Enders MVZ GbR, 70193, Stuttgart, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Containment</Keyword><Keyword MajorTopicYN="N">Neutralisation</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37130476</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2023.105471</ArticleId><ArticleId IdType="pii">S1386-6532(23)00094-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle>